The Guanine Nucleotide Exchange C9orf72 pipeline drugs market research report outlays comprehensive information on the Guanine Nucleotide Exchange C9orf72 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Guanine Nucleotide Exchange C9orf72 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

Smarter leaders trust GlobalData

The report also covers products from therapy areas such as Central Nervous System which include the indications Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia (FTD). It also reviews key players involved in Guanine Nucleotide Exchange C9orf72 targeted therapeutics development with respective active and dormant or discontinued products.

The Guanine Nucleotide Exchange C9orf72 pipeline targets constitutes close to 12 molecules. Out of which, approximately 11 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Preclinical, and Discovery stages are 8, and 3 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.

Guanine Nucleotide Exchange C9orf72 overview

Guanine nucleotide exchange C9orf72 (C9orf72) is a component of the C9orf72-SMCR8 complex, a complex that has guanine nucleotide exchange factor (GEF) activity and regulates autophagy. In the complex, C9orf72 and SMCR8 probably constitute the catalytic subunits that promote the exchange of GDP to GTP, converting inactive GDP-bound RAB8A and RAB39B into their active GTP-bound form, thereby promoting autophagosome maturation.

For a complete picture of Guanine Nucleotide Exchange C9orf72’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.